Melane Sampson, Author at BioTuesdays

Executive Moves

E.F. Hutton appoints healthcare investment banking veteran Bryan Kobel as managing director

Global investment bank E.F. Hutton & Co. has announced the appointment of former public company CEO Bryan Kobel as managing director. Mr. Kobel rejoins E.F. Hutton, where he previously served as managing director...

June 15, 2026

Developments

Faron unveils immunotherapy data in myeloid malignancies at EHA

Faron Pharmaceuticals (AIM: FARN; First North: FARON) announced a poster presentation highlighting biological evidence from the BEXMAB Phase 1/2 trial validating its first-in-class immunotherapy candidate, bexmarilimab...

June 15, 2026

Developments

Context reports positive data for CTIM-76 in PROC

Context Therapeutics (NASDAQ: CNTX) has announced positive interim Phase 1 clinical data for its CLDN6 x CD3 T cell engaging bispecific antibody, CTIM-76, in advanced, late-line platinum-resistant ovarian cancer (PROC)...

June 15, 2026

Developments

Evaxion presents new data for off-the-shelf AML vaccine

Evaxion (NASDAQ: EVAX) has announced new preclinical data for EVX-04, an AI-designed off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML) that targets multiple endogenous retrovirus (ERV) tumor antigens...

June 11, 2026

Developments

60 Degrees signs licensing agreement with Florida State for botanical supplement

60 Degrees Pharmaceuticals (NASDAQ: SXTP; SXTPW) has announced that it has executed a patent licensing agreement with Florida State University to commence large-scale production techniques to extract and purify...

June 11, 2026

Developments

Caribou reports long-term vispa-cel data in r/r B-NHL

Caribou Biosciences (NASDAQ: CRBU) has announced that vispa-cel, its off-the-shelf CD19-targeted CAR-T cell therapy, produced durable long-term responses in patients enrolled in the ANTLER phase 1 clinical trial for...

June 11, 2026

Developments

Cantargia reports launch of investigator-led lung cancer prevention study

Cantargia (STO: CANTA) has announced that the first patient has been dosed in a Phase 2 clinical trial investigating nadunolimab in up to 59 current or previous smokers with multifocal high-risk lung nodules, and at...

June 10, 2026

Developments

Sensorion selects SENS-601 for hearing loss as lead program; files for trials in Canada and France

Sensorion (EPA: ALSEN) announced the selection of SENS-601 which addresses GJB2-related hearing loss as its lead program. A clinical trial application has been filed in Canada and France to evaluate the safety...

June 10, 2026

Developments

Cullinan shares data from T cell engager programs targeting autoimmune diseases

Cullinan Therapeutics (NASDAQ: CGEM) has reported clinical data and outlined global clinical development plans for CLN-978, a CD19xCD3 T cell engager, and velinotamig, a BCMAxCD3 T cell engager, in autoimmune diseases...

June 10, 2026

Developments

INOVATE selects Perimeter for contribution to advance AI for breast cancer surgery

Perimeter Medical Imaging (TSXV: PINK; OTCQX: PYNKF) has announced it has been selected to receive a contribution from the INOVAIT Pilot Fund to advance next-generation AI capabilities for its flagship product Claire...

June 9, 2026

Author - Melane Sampson

E.F. Hutton appoints healthcare investment banking veteran Bryan Kobel as managing director

Faron unveils immunotherapy data in myeloid malignancies at EHA

Context reports positive data for CTIM-76 in PROC

Evaxion presents new data for off-the-shelf AML vaccine

60 Degrees signs licensing agreement with Florida State for botanical supplement

Caribou reports long-term vispa-cel data in r/r B-NHL

Cantargia reports launch of investigator-led lung cancer prevention study

Sensorion selects SENS-601 for hearing loss as lead program; files for trials in Canada and France

Cullinan shares data from T cell engager programs targeting autoimmune diseases

INOVATE selects Perimeter for contribution to advance AI for breast cancer surgery

Subscribe